Human Fibrinogen Concentrate Market to Reach $2.9 billion, Globally, by 2035 at 11% CAGR: Allied Market Research

PORTLAND, Ore., June 4, 2024 /PRNewswire/ — Allied Market Research published a report, titled, “Human Fibrinogen Concentrate Market by Indication (Congenital Fibrinogen Deficiency and Surgical Procedure), Form (Lyophilized, Powder, and Liquid), and End User (Hospitals, Ambulatory Surgical Centers, and Others): Global Opportunity Analysis and Industry Forecast, 2024-2035″. According to the report, the “human fibrinogen concentrate market” was valued at $0.8 Billion in 2023, and is estimated to reach $2.9 billion by 2035, growing at a CAGR of 11% from 2024 to 2035.


Request Sample of the Report on Human Fibrinogen Concentrate Market Forecast 2035 –

Prime determinants of growth

The human fibrinogen concentrate market is on a steady growth propelled by several pivotal factors. There is rise in global incidence of bleeding disorders necessitating the utilization of human fibrinogen concentrates, particularly in critical surgical procedures where efficient hemostatic agents are indispensable. Concurrently, advancements in biotechnology have ushered in the development of more sophisticated formulations of human fibrinogen concentrates, characterized by enhanced efficacy and safety profiles, thereby amplifying their demand. Furthermore, rise in awareness among healthcare practitioners and patients regarding the therapeutic advantages of fibrinogen concentrate is fostering its adoption, particularly within clinical settings. Hence, these factors are poised to drive substantial growth in the human fibrinogen concentrate market during the forecast period.

Report coverage & details:

Report Coverage


Forecast Period


Base Year


Market Size In 2023

$0.8 Billion

Market Size In 2035

$2.9 Billion


11.00 %

No. Of Pages In Report


Segments Covered

Indication, Form, End User, And Region


Increase In Incidence Of Bleeding Disorders

Growing Demand For Fibrinogen Concentrates In Surgeries

Advancements In Biotechnology Leading To Improved Product Efficacy

Rise In Awareness About The Benefits Of Fibrinogen Concentrate Therapy


Development Of Novel Formulations For Improved Patient Outcomes


High Cost Associated With Fibrinogen Concentrate Therapy

Want to Explore More, Connect to our Analyst- 

Recession Impact

  • During a recession, governments, academic institutions, and private funding sources might decrease investment in research and development (R&D) projects, including human fibrinogen initiatives. This reduction in funding can limit the resources available for conducting research, acquiring new technologies, and hiring skilled personnel.
  • Further, pharmaceutical companies may reassess their R&D priorities and allocate resources to human fibrinogen programs with potentially higher returns on investment or greater market demand. This shift in focus could lead to increased investment in certain therapeutic areas, such as vessel sealing and sealants, while reducing investment in others.

The congenital fibrinogen deficiency segment to maintain its lead position during the forecast period

By indication, the congenital fibrinogen deficiency segment dominated the market in 2023 and is expected to continue this trend during the forecast period. The congenital fibrinogen deficiency segment is expected to grow with a CAGR of 11.3% during the forecast period. Increase in congenital fibrinogen deficiency is due to increase in consanguineous marriages in developing countries.

The liquid segment to grow with a faster growth rate during the forecast period

By form, the liquid segment is expected to register a faster CAGR of 11.3% during the analysis period. This is due to factors such as rise in adoption of liquid fibrinogen concentrates in patients mostly in general surgeries and its longer shelf life, which makes it advantageous in terms of storage and transportation. Liquid human fibrinogen is generally used in reconstructive surgery, cardiac surgery, and cytoreductive surgery for pseudomyxoma peritonei. For instance, according to American Society of Plastic Surgeons, about 1.02 million reconstructive surgeries were performed in 2022.

The hospitals segment to maintain its lead position during the forecast period

By end user, the hospitals segment dominated the market in 2023 and is expected to grow with a CAGR of 11.0% during forecast period. For instance, there were approximately 294 million surgical procedures performed in 2022 globally as per WHO and the number is increasing by around 8-10% year on year. Such increase in the number of surgeries yearly is expected to lead to rise in adoption of surgical sealants such as human fibrinogen; thereby driving the market growth.

For Purchase Enquiry-

North America to maintain its dominance by 2035

Region-wise, North America dominated the market in 2023 and is expected to continue this trend during the forecast period. North America has a strong healthcare system and presence of key players such as CSL and Octapharma. However, the Asia-Pacific region is expected to grow faster during the forecast period. This growth is because of the high geriatric population and the increase in trend of sports related injuries in countries such as India and South Korea.

Leading Market Players: –

  • CSL Behring GmbH
  • Octapharma USA
  • Grifols, S.A.
  • LFB Biomedicaments
  • Shanghai RAAS Blood Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Baxter International Inc.
  • Biotest AG
  • BioRad
  • Harbin Pacific Biopharmaceutical Co., Ltd.

The report provides a detailed analysis of these key players in the global human fibrinogen concentrate market. These players have adopted strategies such as product development and launch to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link:

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


David Correa

1209 Orange Street,

Corporation Trust Center,

Wilmington, New Castle,

Delaware 19801 USA.

Toll Free: +1-800-792-5285

Int’l: +1-503-894-6022

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1-855-550-5975


Follow Us on: LinkedIn Twitter



Cision View original content:

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. takes no editorial responsibility for the same.